...
首页> 外文期刊>Journal of Surgical Oncology >Laparoscopy-assisted distal gastrectomy with D2 lymphadenectomy for T2b advanced gastric cancers: three years' experience.
【24h】

Laparoscopy-assisted distal gastrectomy with D2 lymphadenectomy for T2b advanced gastric cancers: three years' experience.

机译:腹腔镜辅助远端胃切除术与D2淋巴结切除术治疗T2b晚期胃癌:三年的经验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The application of laparoscopy-assisted distal gastrectomy (LADG) with advanced gastric cancer (AGC) is a controversial. The purpose of this study was to assess the possibility of using LADG application to AGC. METHODS: Of 160 patients who underwent LADG with D2 lymphadenectomy between April 2004 and March 2007, 26 patients with stage pT2b were selected and compared to 25 patients of the same stage who underwent open distal gastrectomy (ODG) within same period. The comparison was based on the clinicopathologic characteristics, surgical outcome, and follow-up results. RESULTS: There was no significant difference between LADG and ODG groups in most operation results including complication rates (15.4% vs. 16.0%, P = 1.000) except for less average loss of blood (160.0 ml vs. 215.0 ml, P = 0.012) and longer average operating time (255.0 min vs. 190.0 min, P < 0.001) in LADG. Three-year overall survival rates (88.2% vs. 77.2%; P = 0.246) and disease-free survival rates (71.4% vs. 53.4%; P = 0.757) were not significantly different in LADG and ODG groups. CONCLUSIONS: The early results of current study suggest that LADG for AGC is technically safe and oncologically feasible. Therefore, LADG should be considered as a curative treatment for AGC not exposed to serosa.
机译:背景:腹腔镜辅助远端胃切除术(LADG)与晚期胃癌(AGC)的应用存在争议。本研究的目的是评估将LADG应用于AGC的可能性。方法:在2004年4月至2007年3月间行LADG D2淋巴结清扫术的160例患者中,选择了26例pT2b分期的患者,并与同一时期25例行开放性远端胃切除术(ODG)的患者进行了比较。比较是基于临床病理特征,手术结果和随访结果。结果:在包括并发症发生率在内的大多数手术结果中,LADG组和ODG组之间没有显着差异(分别为10.0%和16.0%,P = 1.000),但平均失血量较少(160.0 ml和215.0 ml,P = 0.012)。 LADG的平均操作时间更长(255.0分钟vs. 190.0分钟,P <0.001)。 LADG和ODG组的三年总体生存率(88.2%对77.2%; P = 0.246)和无病生存率(71.4%对53.4%; P = 0.757)没有显着差异。结论:当前研究的早期结果表明,LADG用于AGC是技术上安全且在肿瘤学上可行的。因此,应将LADG视为不暴露于浆膜的AGC的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号